A Phase II, Open-Label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Naive Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Grants and Contracts Details

StatusFinished
Effective start/end date9/21/10 → 8/31/12

Funding

  • EMD Serono Incorporated: $52,737.00